

CURRICULUM VITAE

MARK C. KELLEY, MD, MMHC, FACS

CURRENT POSITION

Associate Professor of Surgery
Vanderbilt University Medical Center

CLINIC ADDRESS

2105 Edward Curd Lane, Suite 102
Franklin, TN 37067

Work Phone: 615-791-7253
Work Fax: 615-791-7383
Work e-mail: mark.kelley@vanderbilt.edu
www.linkedin.com/pub/mark-kelley/10/24g/566/
www.doximity.com/pub/mark-kelley-ma/4
NPI: 1174622500
ORCID ID: 0000-0002-5188-1931

DATE OF BIRTH

August 17, 1964 (Tacoma, Washington USA)

EDUCATION

UNDERGRADUATE

7/82 – 7/85
5/23/86

University of Florida, Gainesville, Florida
Major: Interdisciplinary Studies
Bachelor of Science (High Honors)

MEDICAL SCHOOL

8/85 – 5/89
5/27/89

University of Florida, Gainesville, Florida
College of Medicine
Doctor of Medicine (Honors)

RESIDENCY

7/89 – 6/95
6/91 – 6/92
7/94 – 6/95

University of Florida, Gainesville, Florida
General Surgery Resident
Surgical Research Resident
Chief Resident

FELLOWSHIP

7/95 – 7/97

John Wayne Cancer Institute, Santa Monica, California
Surgical Oncology Fellow

GRADUATE

8/08 – 9/09
09/03/2009

Vanderbilt University Nashville, Tennessee
Owen Graduate School of Management
Masters of Management in Health Care

LICENSURE

Tennessee Board of Medical Examiners

License # MD-29494 Certified 7/97 CAQH # 10837794	Active Expires 8/17/19
The Medical Board of California License # GO-81320 Certified 4/95	Inactive Expired 8/97
Florida Board of Medical Examiners License # ME-60333 Certified 7/91	Inactive Expired 12/95
Drug Enforcement Administration License # FK-5884083 Certified 9/91; New # 4/16	Active Expires 12/31/18

CERTIFICATION

12/12 Re-Certified	American Board of Surgery		
4/96 Certified	American Board of Surgery	Candidate: 051875	Certificate: 041148
6/90 Certified	National Board of Medical Examiners		

ADMINISTRATIVE EXPERIENCE / TRAINING

03/15 – 12/15	Medical Director of Oncology, CHI – Memorial Hospital
10/02 – 03/15	Chief, Division of Surgical Oncology and Endocrine Surgery
7/01 – 9/02	Acting Chief, Division of Surgical Oncology
7/97 – 8/05	Clinical Director, Vanderbilt Breast Center
12/00 – 06/12	Chairman, Vanderbilt University Medical Center Cancer Committee
07/08 – 06/12	Medical Director, General Surgery “POD”, VUMC Operative Services
7/01 – 6/09	Vanderbilt Cancer Patient Care Center Clinic Operations Committee
2007	VUMC Academic Leadership Program
2007, 2008	VUMC Medical Philanthropy Training

PROJECT MANAGEMENT EXPERIENCE

2006 – 2008	Member, VICC Clinic Redesign Committee
2007 – 2008	Member, Vanderbilt Breast Center at 100 Oaks Planning Committee
2008 – 2009	MMHC Clinic Operations Research and Design Project Team
2010 – 2011	Chair, Division of Surgical Oncology Leadership Development Team
2013 – 2014	Member, VICC Operations Improvement and Leadership Team
2013 – 2014	Co-Chair, Surgery Core Committee, VUMC APRN Practice Design Team

MEDICAL STAFF APPOINTMENTS

07/16 – Present	Vanderbilt University Medical Center Nashville, Tennessee (Active Staff)
06/16 – Present	Williamson Medical Center Franklin, Tennessee (Active Staff)

03/15 – 12/15 CHI – Memorial Hospital
Chattanooga, TN (Active Staff)

07/97 – 03/15 Vanderbilt University Medical Center
Nashville, Tennessee (Active Staff)

ACADEMIC APPOINTMENTS

Vanderbilt University; Nashville, Tennessee
7/97 - 6/03 Assistant Professor of Surgery
7/03 - 03/15 Associate Professor of Surgery
03/15 – 07/16 Adjunct Associate Professor of Surgery
7/16 - Present Associate Professor of Surgery

OTHER PROFESSIONAL EXPERIENCE

01/16 – Present Innov8 Cancer Care
Founder, Chief Medical Officer
Cancer and Surgical Practice Management and Redesign Consulting

03/13 – 07/13 navi Health, inc. Nashville, Tennessee
Part-Time Medical Director, Post-Acute Care

COMMITTEES

1998 - 2001 Society of Surgical Oncology Issues and Government Affairs Committee
2003 Vanderbilt University Medical Center Thoracic Surgery Search Committee
2005 - 2006 American Society of Breast Surgeons Quality and Patient Safety Committee
2009 - 2015 National Comprehensive Cancer Network (NCCN) Melanoma Practice
Guidelines Committee
2013 - 2015 American Board of Surgery Certifying Exam Skin / Soft Tissue Committee
2013- Present Society of Surgical Melanoma and Sarcoma Disease Site Work Group
2014 American Board of Surgery, Associate Examiner

HONORS AND AWARDS

1982 Eagle Scout, Boy Scouts of America
1986 Phi Beta Kappa
1988 Alpha Omega Alpha, Junior Class Election
1989 Robert Donohoe Award in General Surgery
1989 Florida Obstetric and Gynecologic Society Award
1989 Walter Oppelt Award for Pharmacology Research
1992 Surgical Research Award
1995 Outstanding Teaching Resident
1995 Edward R. Woodward Award
2007 - Present Castle-Connelly “America’s Top Doctors”
2008 - 2013 PRC “5 Star Performer” (Top 10%) for Patient Satisfaction
2011 - Present Best Doctors Inc, “Best Doctors in America”
2013 - 2014 Nashville Magazine: “Nashville’s Top Doctors”

2013 “America’s Top Physicians for Cancer”
2014 PRC “Top Performer” (Top 1%) for Patient Satisfaction

MEMBERSHIPS

Association for Academic Surgery
American Association for Cancer Research
American College of Surgeons (Fellow, 10/01) Member: 03018078
American Society of Breast Surgeons
American Society for Clinical Oncology
Leadership Healthcare
Nashville Health Care Council
Nashville Surgical Society
H. William Scott, Jr. Society
Society of Surgical Oncology (Fellow, 03/99)
Southeastern Surgical Congress
Southern Surgical Association (Fellow, 12/11)
Edward R. Woodward Society (President 2014 - 2015)

EDITORIAL EXPERIENCE

1999 - Present Ad Hoc Reviewer, Journal of Surgical Research
2000 - 2016 Ad Hoc Reviewer, Annals of Surgical Oncology
2003 Ad Hoc Reviewer, New England Journal of Medicine
2004 - Present Ad Hoc Reviewer, Cancer
2005 Ad Hoc Reviewer, Surgery
2007 - 2008 AVON/NCI P01 Reviewer, NIH/NCI
2013 - Present Ad Hoc Reviewer, Annals of Surgery
2016 Ad Hoc Reviewer, PLOS One
2016- Present Board Member, Breast Section, Annals of Surgical Oncology

TEACHING EXPERIENCE

07/97 - 06/03 Vanderbilt University School of Medicine
Assistant Professor of Surgery
07/03 - 03/15 Associate Professor of Surgery
03/15 – Present Adjunct Associate Professor of Surgery

MENTORING EXPERIENCE

CLINICAL:

1. **Kenneth Richards, M.D.:** Endocrine Surgery Fellow, 1999-2000.
Current Position: General / Endocrine Surgeon, Private Practice, Roanoke VA.
2. **Glen Balch, M.D.:** Surgical Research Resident 2002-2003.
Current Position: Surgical Oncologist, UT Southwestern Medical Center, Dallas TX.
3. **Laura Lawson, M.D.:** Breast Surgery Fellow, 2003-2004.
Current Position: Breast Surgeon, Private Practice, Nashville TN.
4. **Rachel Forbes, M.D.:** Research Resident, 2004-2005.

Current Position: Transplant Surgeon, VUMC, Nashville TN.

5. **Alison Hatmaker, M.D.:** Breast Surgery Fellow, 2005-2006; 2008-2009.
Current Position: Breast Surgeon, Private Practice, Louisville KY.
6. **Brian Gray, M.D.:** Research Student, 2005-2006.
Current Position: Resident, General Surgery, University of Michigan, Ann Arbor MI.
7. **Alfred Mansour, M.D.:** Research Resident, 2007-2008.
Current Position: Orthopaedic Surgeon, Nashville TN.
8. **Rebecca Snyder, M.D.:** Research Resident, 2011-2013.
Current Position: Fellow, Surgical Oncology, MD Anderson Cancer Center, Houston TX.
9. **Chelsea Isom, M.D.:** Research Resident, 2013- 2015.
Current Position: Resident, General Surgery, VUMC, Nashville TN.
10. **Alexander Hysong:** Undergraduate Research Student, 2013 - 2015
Current Position : Medical Student, Vanderbilt University, Nashville TN.

RESEARCH:

1. **Jao Jih Ou:** Dissertation for the degree of PhD in Biomedical Engineering. “Development of Modality-Independent Elastography as a Method of Breast Cancer Detection”, 2006-2007. Committee Member - Michael Miga PhD, Chair.
2. **William Hardesty:** Dissertation for the degree of PhD in Chemistry. “Histology-Directed MALDI-MS for the Identification of Protein Biomarkers in Melanoma”, 2007-2008. Committee Member – Richard Caprioli PhD, Chair.
3. **Matthew Keller:** Dissertation for the degree of PhD in Biomedical Engineering. “Optical Spectroscopy Imaging for the Evaluation of Breast Cancer Surgical Margins”, 2008-2009. Committee Member – Anita Mahadevan-Jansen PhD, Chair.
4. **Deon Doxie:** Dissertation for the degree of PhD in Cancer Biology. “Tumor Heterogeneity and Targeted Therapy of Melanoma”, 2013-Present. Committee Member – Jonathan Irish PhD, Chair.

RESEARCH INTERESTS

CLINICAL:

Quality Improvement and Clinical Outcomes Research in Melanoma and Breast Cancer
Clinical Trials of Molecular Targeted Therapy for Melanoma and Breast Cancer
Clinical Trials of Lymph Node Management in Melanoma and Breast Cancer
Development and Application of New Technologies in Cancer Treatment
Tissue Acquisition and Analysis for Personalized Cancer Therapy

BASIC / TRANSLATIONAL:

Molecular and Cellular Biology of Melanoma and Breast Cancer

Biomarkers of Treatment Response and Outcome in Melanoma
Preclinical Models for the Evaluation of Molecular Targeted Therapy in Melanoma

BUSINESS / MANAGEMENT:

Strategies for the Delivery of Value-Based Cancer Care
Disruptive Innovation in Health Care Delivery Systems
Integration of Advanced Practice Clinicians into Multidisciplinary Cancer Care
Strategies for Improving the Quality of Cancer Care in Low Resource Environments

RESEARCH PROTOCOLS

CLINICAL TRIALS:

VICC MEL-9701

Schering-Plough Corporation

Closed

A multicenter trial of adjuvant interferon alfa-2b for melanoma patients with early lymph node metastasis detected by lymphatic mapping and sentinel lymph node biopsy.

Role: **Site Principal Investigator**

VICC BRE-9702

No Extramural Funding

Closed

Sentinel node mapping for breast cancer: a pilot study

Role: **Principal investigator**

VICC BRE-9703

Department of Defense (DOD) through Moffitt Cancer Center

Closed

Early detection of occult micro metastases by lymph node mapping and RT-PCR in patients with invasive breast cancer: A multi-center trial

Role: **Site Principal Investigator**

VICC MEL-9807

NCI and CancerVax Corporation

Closed

A phase III randomized double-blind trial of immunotherapy with a polyvalent melanoma vaccine (C-VAX) plus BCG versus placebo plus BCG as a post-surgical treatment for stage IV melanoma.

Role: **Site Principal Investigator**

VICC MEL-9838

NCI and CancerVax Corporation

Closed

A phase III randomized double-blind pivotal trial of immunotherapy with BCG plus a polyvalent melanoma vaccine (C-VAX) versus BCG plus placebo as a post-surgical treatment for stage III melanoma.

Role: **Site Principal Investigator**

ECOG BRE-E5194

Eastern Cooperative Oncology Group (ECOG)

Closed

Local excision alone for selected patients with DCIS of the breast.

Role: **Site Co-Investigator**

ECOG BRE-C9343

Eastern Cooperative Oncology Group (ECOG)

Closed

Evaluation of lumpectomy, tamoxifen, and irradiation of the breast compared with lumpectomy plus tamoxifen in

women 70 years of age or older with breast cancer that is less than or equal to 2 cm in size: A phase III study.

Role: **Site Co-Investigator**

VICC BRE-9901

National Surgical Adjuvant Breast and Bowel Program (NSABP)

Closed

NSABP Protocol P2: Study of tamoxifen and Raloxifene for the prevention of breast cancer.

Role: **Site Principal Investigator**

VICC BRE-9945

Pro-Duct Health Corporation

Closed

Identification of intraductal breast pathology in high-risk women: a multicenter trial.

A prospective follow-up study evaluating ductal lavage cytology in women at high risk of developing breast cancer.

Role: **Site Principal Investigator**

VICC BRE-9936

VICC SPORE in Breast Cancer NCI: P50-CA-98131-01

Closed

A pilot study of therapy utilizing neoadjuvant paclitaxel and concurrent radiation in stage II/III breast cancer.

Role: **Co-Investigator**

VICC IN SUR-0043

American College of Surgeons Oncology Group (ACoSOG)

Closed

ACoSOG Trial Z-10: A prognostic study of sentinel node and bone marrow micrometastasis in women with clinical T1 or T2 No Mo breast cancer.

Role: **Site Principal Investigator**

VICC IN SUR-0044

American College of Surgeons Oncology Group (ACoSOG)

Closed

ACoSOG Trial Z-11: A randomized trial of axillary node dissection in women with clinical T1 or T2 No Mo breast cancer who have a positive sentinel node.

Role: **Site Principal Investigator**

VICC BRE 0057

NCI R-01 to Dr. Wei Zheng

Closed

Nashville Breast Health Study

Role: **Co-Investigator**

VICC BRE 0128

NCI SPORE in Breast Cancer P50-CA-98131-01

Closed

HER (erbB) tyrosine kinase inhibitors in treatment-naïve operable breast cancer.

Role: **Co-Principal Investigator**

VICC MEL 0287

No Extramural Funding

Open

Melanoma, pigmented lesion, and cutaneous malignancy biospecimen repository

Role: **Principal Investigator (through -03/15)**

VICC MEL 0474

NCI through John Wayne Cancer Institute

Closed

Multicenter selective lymphadenectomy trial II (MSLT-II).

Role: **Site Principal Investigator**

VICC BRE 0588
NCI SPORE in Breast Cancer P50-CA-98131-01 Closed
MRI evaluation of breast tumor growth and treatment response.
Role: **Co-Investigator**

VICC MEL 0628
FDA FD-R-002-33-01 to Dr. Jeffrey Sosman Closed
Inhibition of NF-kB signaling in melanoma therapy
Role: **Co-Investigator**

VICC BRE 0718
NCI: Vanderbilt Ingram Cancer Center SPORE in Breast Cancer P50-CA-98131-01 Closed
Optical spectroscopy for the evaluation of surgical margins in breast conserving therapy.
Role: **Co-Investigator**

VICC BRE 0776
NCI: Vanderbilt Ingram Cancer Center SPORE in Breast Cancer P50-CA-98131-01 Closed
A pre-surgical trial of letrozole in post-menopausal patients with operable hormone-sensitive breast cancer
Role: **Co-Investigator**

VICC MEL 1036
FDA: 1R01FD003522-01A to Dr. Jeffrey Sosman Closed
A phase II correlative clinic trial of MLN8237, a selective Aurora Kinase A (AURKA) inhibitor, in patients with unresectable stage III or IV melanoma.
Role: **Co-Principal Investigator**

VICC MEL 1263
National Comprehensive Cancer Network / Glaxo – Smith Kline VUMC 39458 Closed
Biomarkers of response and resistance to sequential BRAF and MEK targeted therapy in a pre-surgical model of advanced, operable melanoma.
Role: **Principal Investigator**

VICC BRE 1277
NIH/NCI (1U01CA174706-01) Thomas Yankeelov, PhD Closed
Ultra-high field (7 Tesla) MRI / MRS evaluation of breast cancer
Role: **Co-Investigator (through 03/15)**

VICC BRE 1298
No Extramural Funding Open
A safety and efficacy study of intra-operative radiation therapy (IORT) using the Xofigo Axxent system at the time of breast conserving surgery for early stage breast cancer.
Role: **Co-Investigator (through 03/15)**

BASIC AND TRANSLATIONAL SCIENCE:

NCI R-01 (Ann Richmond, PhD) Complete
The role of NF-kappa-B dysregulation in melanoma tumor progression.
Role: **Collaborator**

American Cancer Society Institutional Research Grant IRG-58-009-42 Complete
Autologous dendritic cells loaded with tumor-derived apoptotic bodies for immunotherapy of melanoma.

Role: **Principal Investigator**

V Foundation (Ann Richmond, PhD)

Complete

Molecularly-Based Targeted Therapy of Melanoma.

Role: **Co-Investigator**

National Comprehensive Cancer Network / Glaxo – Smith Kline VUMC 39458 (\$254,490, two years) Closed

Biomarkers of response and resistance to sequential BRAF and MEK targeted therapy in a pre-surgical model of advanced, operable melanoma.

Role: **Principal Investigator**

Vanderbilt Ingram Cancer Center, Provocative Questions Pilot Project (\$100,000, one year)

Complete

Targeting signaling networks in subpopulations of B-RAF mutation positive melanoma cells during B-RAF and MEK targeted therapy.

Role: **Co-Principal Investigator**

Melanoma Research Foundation (Jeffrey Sosman, MD) (\$750,000, two years)

Closed

Comprehensive genomic characterization of acral melanoma.

Role: **Co-Investigator (though 03/15)**

VA Merit Review Award (Ann Richmond, PhD) (\$1,000,000, three years)

Active

Modeling New Therapeutic Approaches for Malignant Melanoma.

Role: **Co-Investigator (through 03/15)**

NIH NCI R-01 (Jonathan Irish, PhD, PI)

Pending

Targeting Therapy Resistant Melanoma with Single Cell Biology

Role: **Co-Investigator**

PATENTS

- 1) **“Spatially-offset Raman spectroscopy of layered soft tissues and applications of same”**.
Application # 12/632,637. (VU 0916US1). Granted December 7, 2009.
- 2) **“Device for fixation and evaluation of tissue samples for spectroscopy and related applications”**.
Application Pending.

BIBLIOGRAPHY

Original Manuscripts

1. O'Malley CA, Hautamaki RD, **Kelley MC**, Meyer EM. Effects of ovariectomy and estradiol benzoate on high affinity choline uptake, acetylcholine synthesis and release from rat cerebral cortical synaptosomes. *Brain Research*. 1987 Feb 17; 403:389-392. PMID: 3828829.
2. **Kelley MC**, Raizada MK, Meyer EM. Pharmacological characterization of high affinity choline transporters in primary neuronal cultures in rat brain. *Neuropharmacology*. 1988 Aug; 27(8): 837-842. PMID: 3216963.
3. **Kelley MC**, Hocking MP, Marchand SD, Sninsky CA. Ketorolac prevents postoperative small intestinal ileus in rats. *American Journal of Surgery*. 1993 Jan; 165(1): 107-112. PMID: 9095325.
4. Espat NJ, Cheng G, **Kelley MC**, Vogel SB, Sninsky CA, Hocking MP. Vasoactive intestinal peptide and substance P receptor antagonists improve postoperative ileus. *Journal of Surgical Research*. 1995 Jun; 58(6): 719-723. PMID: 7540700.
5. Jones RC, **Kelley MC**, Gupta RK, Nizze JA, Yee R, Leopoldo Z, Qi K, Stern S, Morton DL. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model. *Annals of Surgical Oncology*. 1996 Sep; 3(5): 437-445. PMID: 8876885.
6. Ravindranath MH, Bauer PM, Amiri AA, Miri SM, **Kelley MC**, Morton DL. Cellular cancer vaccine induces delayed-type hypersensitivity reaction and augments antibody response to tumor-associated carbohydrate antigens better than soluble lysate cancer vaccine. *Anti-Cancer Drugs*. 1997 Mar; 8: 217-224. PMID: 9095325.
7. Ravindranath MH, Amiri AA, Bauer PM, **Kelley MC**, Essner R, Morton DL. Endothelial-selectin ligands sialyl-Lewis^x and sialyl-Lewis^a are differentiation antigens immunogenic in human melanoma. *Cancer*. 1997 May 1; 79: 1686-1697. PMID: 9128983.
8. Bostick P, Essner R, Sarantou T, **Kelley M**, Glass E, Foshag LJ, Stern S, Morton DL. Intraoperative lymphatic mapping for early-stage melanoma of the head and neck. *American Journal of Surgery*. 1997. Nov; 174:536-539. PMID: 9374232.
9. Ravindranath MH, **Kelley MC**, Jones RC, Amiri AA, Bauer PM, Morton DL. Ratio of IgG:IgM antibodies to Sialyl-Lewis^x and GM₃ correlates with tumor growth after immunization with melanoma cell vaccine with different adjuvants in mice. *International Journal of Cancer*. 1998 Jan 5; 75(1):117-24. PMID: 9426699.
10. **Kelley MC**, Jones RC, Gupta R, Wanek L, Morton DL. Tumor-associated antigen TA-90 immune complex assay detects occult metastases in early-stage melanoma. *Cancer*. 1998 Oct 1; 83(7): 1355-61. PMID: 9762936.
11. Bostick P, Essner R, Glass E, **Kelley M**, Sarantou T, Foshag LJ, Qi K, Morton DL. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. *Archives of Surgery*. 1999 Jan; 134(1):43-9. PMID: 9927129.
12. Essner, R Conforti A, **Kelley MC**, Foshag LJ, Stern S, Morton DL. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. *Annals of Surgical Oncology*. 1999 Jul-Aug 6(5):442-9. PMID: 10458681.

13. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, **Kelley MC**, Ye W, Glass E, Turner RR. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. *Journal of Clinical Oncology*. 2000 Jul; 18(13):2553-9. PMID: 10893286.
14. Chakravarthy A, Nicholson B, **Kelley M**, Beauchamp RD, Johnson D, Frexes-Steed M, Simpson J, Shyr Y, Pietenpol J. A pilot study of neoadjuvant paclitaxel and radiation with correlative molecular studies in stage II/III breast cancer. *Clinical Breast Cancer*. 2000 1(1):68-20. PMID: 11899393.
15. Bilchik A, Miyashiro M, **Kelley M**, Kuo C, Fujiwara Y, Nakamori S, Monden M, Hoon DS. Molecular detection of metastatic pancreatic carcinoma cells using multimarker reverse transcriptase-polymerase chain reaction assay. *Cancer*. 2000 Mar 1; 88(5) 1037-44. PMID: 10699892.
16. **Kelley MC**, Hsueh E, Jones RC, Gupta RK, Yee R, Stern S, Morton DL. Tumor-associated antigen TA-90 immune complex assay predicts recurrence and survival after surgical resection of stage I-III melanoma. *Journal of Clinical Oncology*. 2001 Feb 15; 19(4):1176-82. PMID: 11181684.
17. Dooley WC, Lyung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RA, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, **Kelley MC**, et al.. Ductal lavage for detection of cellular atypia in women at high risk of breast cancer. *Journal of the National Cancer Institute*. 2001 Nov 7; 93(21):1624-32. PMID: 11698566.
18. Molpus KL, **Kelley MC**, Johnson JE, Martin WH, Jones HW. Sentinel lymph node detection and microstaging in vulvar carcinoma. *Journal of Reproductive Medicine*. 2001 Oct; 46(10) 863-869. PMID: 11725728.
19. Ludwig V, Rice MH, Martin WH, **Kelley MC**, Delbeke D. 2-Deoxy-2-[¹⁸F]Fluoro-D-Glucose Positron Emission Tomography Uptake in a Giant Adrenal Myelolipoma. *Molecular Imaging and Biology*. 2002 Oct; 4(5):355-358. PMID: 14537110.
20. Balch GC, Mithani SK, Richards K, Beauchamp RD, **Kelley MC**. Prospective evaluation of lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. *Annals of Surgical Oncology*. 2003 Jul; 10(6):616-621. PMID: 12839845.
21. **Kelley MC**, Hansen N, McMasters KM. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. *Am J Surg*. 2004 Jul; 188(1):49-61. (Review) PMID: 15219485.
22. Lawson LL, Sandler M, Martin W, Beauchamp RD, **Kelley MC**. Preoperative lymphoscintigraphy and internal mammary sentinel lymph node biopsy does not enhance the accuracy of lymphatic mapping for breast cancer. *The American Surgeon*. 2004 Dec; 70(12) 1050-55. PMID: 15663043.
23. Balch GC, Mithani SK, Simpson J, **Kelley MC**. Accuracy of gross evaluation of surgical margin status in women undergoing partial mastectomy for breast malignancy. *The American Surgeon*. 2005 Jan; 71(1): 22-7, 2005. PMID: 15757052.
24. Forbes RC, Balch GC, **Kelley MC**. Selective Use of Intraoperative Touch Prep Analysis of Sentinel Nodes in Breast Cancer. *The American Surgeon*. 2005 Nov; 71(11): 955-60. PMID: 16372615.
25. Chakravarthy B, **Kelley MC**, McLaren B, Truica CI, Billheimer D, Mayer IA, Grau AM, Johnson DH, Simpson JF, Beauchamp RD, Jones C, Pietenpol J. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. *Clinical Cancer Research*. 2006 Mar 1; 12(5):1570-6. PMID: 16533783.

26. Tomkova K, El-Rifai W, Vilgelm A, **Kelley MC**, Wang T, Zaika AI. The gastrin gene promoter is regulated by p73 protein isoforms in tumor cells. *Oncogene*. 2006 Sep 28; 25(44):6032-6. PMID: 16636659.
27. Yankeelov TE, Lepage M, Chakravarthy AB, Broome EE, Niermann KJ, **Kelley MC**, Meszoely IM, Mayer IA, Herman CR, McManus K, Price RR, Gore JC. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: Initial results. *Magnetic Resonance Imaging*. 2007 Jan; 25(1):1-13, 2007. PMID: 17222711.
28. Belkhiri A, Dar AA, Zaika A, **Kelley M**, El-Rifai W. t-Darpp promotes cancer cell survival by upregulation of Bcl2 through Akt-dependent mechanism. *Cancer Research*. 2008 Jan 15; 68(2):395-403. doi: 10.1158/0008-5472.CAN-07-1580. PMID: 18199533.
29. Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop ID, **Kelley MC**, Arteaga CL. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. *Journal of Clinical Oncology*. 2008 Feb 20; 26(6):897-906. doi: 10.1200/JCO.2007.13.5939. PMID: 18180460.
30. Majumder SK, Keller MD, Boulos FI, **Kelley MC**, Mahadevan-Jansen A. Comparison of autofluorescence, diffuse reflectance, and Raman spectroscopy for breast tissue discrimination. *Journal of Biomedical Optics*. 2008 Sep-Oct; 13(5):054009. doi: 10.1117/1.2975962. PMID: 19021389.
31. Li X, Dawant BM, Welch EB, Chakravarthy AB, Freehardt D, Mayer I, **Kelley M**, Meszoely I, Gore JC, Yankeelov TE. A non-rigid registration algorithm for longitudinal breast MR images and the analysis of breast tumor response. *Magnetic Resonance Imaging*. 2009 Nov; 27(9):1258-70. doi: 10.1016/j.mri.2009.05.007. PMID: 19525078.
32. Planey CR, Welch EB, Xu L, Chakravarthy AB, gatenby JC, Freehardt D, Mayer I, Meszoely I, Kelley M, Means-Powell J, Gore JC, Yankeelov TE. Temporal scanning requirements for reference region modeling of DCE-MRI data in human breast cancer. *Journal of Magnetic Resonance Imaging*. 2009 Jul; 30(1):121-34. doi: 10.1002/jmri.21812. PMID: 19557727.
33. Li X, Dawant B, Welch EB, Chakravarthy AB, Xu L, mayer I, Kelley M, Meszoely I, means-Powell J, Gore JC, Yankeelov TE. Validation of an algorithm for the nonrigid registration of longitudinal breast MR images using realistic phantoms. *Medical Physics*. 2010 Jun; 37(6):2541-52. PMID: 20632566.
34. Tastas AD, Keedy VL, Florell SR, Simpson JF, Coffin CM, **Kelley MC**, Cates, JM. Foamy Cell Angiosarcoma: A Rare and Deceptively Bland Variant of Cutaneous Angiosarcoma. *Journal of Cutaneous Pathology* 2010 Aug; 37(8):901-6. doi: 10.1111/j.1600-0560.2010.01512.x. PMID: 20175826.
35. Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, **Kelley MC**, Puzanov I, Richmond A, Sosman JA. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. *Clinical Cancer Research*. 2010 Jan 1; 16(1):348-57. doi: 10.1158/1078-0432.CCR-09-2087. PMID: 20028756.
36. Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley, EH, De Matos Granja-Ingram N, Olivares MG, **Kelley MC**, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, Formenti SC, Caprioli RM, Pietenpol JA. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. *Clinical Cancer Research*. 2010 Jan 15; 16(2):681-90. doi: 10.1158/1078-0432.CCR-09-1091. PMID: 20068102.

37. Mansour AA 3rd, **Kelley MC**, Hatmaker AR, Hold GE, Schwartz HS. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging. *Annals of Surgical Oncology*. 2010 Apr; 17(4):1144-51. doi: 10.1245/s10434-009-0843-4. PMID: 19967460.
38. Keller MD, Majumder SK, **Kelley MC**, Meszoely IM, Boulos FI, Olivares GM, Mahadevan-Jansen A. Autofluorescence and diffuse reflectance spectroscopy and spectral imaging for breast surgical margin analysis. *Lasers in Surgery and Medicine*. 2010 Jan; 42(1):15-23. Doi: 10.1002/lsm20865. PMID: 20077490.
39. Long J, Cai Q, Shu XO, Qu S, Li C, Zheng Y, Gu K, Wang W, Xiang YB, Cheng J, Chen K, Zhang L, Zheng H, Shen CY, Huang CS, Hou, MF, Shen H, Hu Z, Wang F, Deming SL, **Kelley MC**, Shrubsole MJ, Khoo US, Chan KY, Chan SY, Haiman CA, Henderson BE, Le Marchand L, Iwasaki M, Kasuga Y, Tsugane S, Matsuo K, Tajima K, Iwata H, Huang B, Shi J, Li G, Wen W, Gao YT, Lu W, Zheng W. Identification of a functional genetic variant at 16q12.1 for breast cancer risk: results from the Asia Breast Cancer Consortium. *PLoS Genetics*. 2010 Jun 24; 6(6):e1001002. doi: 10.1371/journal.pgen.1001002. PMID: 20585626.
40. Fu Z, Deming SL, Fair AM, Shrubsole MJ, Wujcik DM, Shu X-O, **Kelley MC**, Zheng W. Well-done meat intake and meat-derived mutagen exposures in relation to breast cancer risk: The Nashville Breast Health Study. *Breast Cancer Research and Treatment*. 2011 129(3):919-928.
41. Fohn LE, Rodriguez A, **Kelley MC**, Ye F, Shyr Y, Stricklin G, Robbins JB. D2-40 lymphatic marker for detecting lymphatic invasion in thin to intermediate thickness melanomas: association with sentinel lymph node status and prognostic value-a retrospective case study. *Journal of American Academy of Dermatology*, 2011 Feb; 64(2):336-45. doi: 10.1016/j.jaad.2010.03.005. PMID: 21238827.
42. Arlinghaus LR, Welch EB, Chakravarthy AB, Xu L, Farley JS, Abramson VG, Grau AM, **Kelley MC**, Mayer IA, Means-Powell JA, Meszoely IM, Gore JC, Yankeelov TE. Motion correction in diffusion-weighted MRI of the breast at 3T. *Journal of Magnetic Resonance Imaging*. 2011 5(33):1063-70. doi: 10.1002/jmri.22562. PMID: 21509862.
43. Hardesty WM, **Kelley MC**, Mi D, Low RL, Caprioli RM. Protein signatures for survival and recurrence in metastatic melanoma. *Journal of Proteomics*. 2011 Jun 10; (74):1002-14. doi: 10.1016/j.jprot.2011.04.013. PMID: 21549228.
44. Keller MD, Vargis E, de Matos Granja N, Wilson RH, Mycek MA, **Kelley MC**, Mahadevan-Jansen A. Development of a spatially offset Raman spectroscopy probe for breast tumor surgical margin evaluation. *Journal of Biomedical Optics*. 2011 Jul; 16(7):077006. doi: 10.1117/1.3600708. PMID: 21806286.
45. Li X, Welch EB, Arlinghaus LR, Chakravarthy AB, Xu L, Farley J, Loveless ME, Mayer IA, **Kelley MC**, Meszoely IM, Means-Powell JA, Abramson VG, Grau AM, Gore JC, Yankeelov TE. A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer. *Physics in Medicine and Biology*. 2011 Sep 7; 56(17):5753-69. doi: 10.1088/0031-9155/56/17/018. Epub 2011 Aug 12. PMID: 21841212.
46. Poulidakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, **Kelley MC**, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). *Nature*. 2011 Nov 23;480(7377):387-90. doi: 10.1038/nature10662. PMID: 22113612.
47. Li X, Welch EB, Chakravarthy AB, Xu L, Arlinghaus LR, Farley J, Mayer IA, **Kelley MC**, Meszoely IM,

- Means-Powell J, Abramson VG, Grau AM, Gore JC, Yankeelov TE. Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer. *Magnetic Resonance in Medicine*. 2012 Jul;68(1):261-71. doi: 10.1002/mrm.23205. Epub 2011 Nov 29. PMID: 22127821.
48. Hoshimoto S, Faries MB, Morton DL, Shingai T, Kuo C, Wang HJ, Elashoff R, Mozzillo N, **Kelley MC**, Thompson JF, Lee JE, Hoon DS. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. *Annals of Surgery*. 2012 Feb; 255(2):357-62. doi: 10.1097/SLA.0b013e3182380f56. PMID: 22202581.
49. Su Y, Vilgelm AE, **Kelley MC**, Hawkins OE, Liu Y, Splittgerber RC, Kantrow S, Short SP, Sobolik-Delmaire T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyer U, Stuart DD, Levy S, Sosman JA, Richmond A. RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors. *Clinical Cancer Research*. 2012 Apr 15; 18(8):2184-98. Doi: 10.1158/1078-0432.CCR-1122. PMID: 22351689.
50. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, **Kelley MC**, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. *PLoS One*. 2012; 7(4):e35309. Doi: 10.1371/journal.pone.0035309. PMID: 22536370.
51. Sexton KW, Poteet SP, Hill JB, Schmidt A, Del Corral GA, Axt J, **Kelley MC**, Thayer WP, Shack RB. Adjuvant radiation therapy increases disease-free survival in stage Ib Merkel cell carcinoma. *Annals of Plastic Surgery*. 2013 Jul 1. Epub ahead of print. PMID: 23657045.
52. Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splitterberger RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, **Kelley MC**, Richmond A. Targeting aurora kinases limits tumor growth through DNA-damage mediated senescence and blockade of Nf-kappaB impairs this drug-induced senescence. *EMBO Molecular Medicine*. 2013 Jan; 5(1):149-66. doi: 10.1002/emmm.201201378. PMID 23180582.
53. Coit DG, Adtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS, **Kelley MC**, Khushalani NI, Kudchadkar RR, Ilange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho M. NCCN Melanoma Clinical Practice Guidelines version 2.2013: Featured updates to the NCCN guidelines. *Journal of the National Comprehensive Cancer Network*. 2013 Apr 1; 11(4):395-407. PMID 23584343.
54. Li X, Arlinghaus LR, Ayers GD, Chkravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, **Kelley MC**, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhawe SR, Yankeelov TE. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: Pilot study findings. *Magnetic Resonance in Medicine*. 2013 May 9. doi: 10.1002/mrm.24782. PMID: 23661583.
55. Xuan D, Li G, Cai Q, Deming-Halverson S, Shrubsole MJ, Shu XO, **Kelley MC**, Zheng W, Long J. APOBEC3 deletion polymorphism is associated with breast cancer risk in women of European ancestry. *Carcinogenesis*. 2013 Oct; 34(10):2240-3. doi 10.1093/carcin/bgt 185. PMID: 23715497.
56. Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, **Kelley MC**, Joseph RW, Sosman JA. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. *Cancer Immunology Research*. 2013 1(60): 373-7. doi 10.1158/2326-6066.CIR-13-0092.

57. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, **Kelley MC**, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. *Cancer Discovery*. 2014 Jan; 4(1):80-93. doi: 10.1158/2159-8290 PMID: 24265155.
58. Coit DG, Thompson JA, Adtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS, **Kelley MC**, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M. NCCN Melanoma Clinical Practice Guidelines version 4.2014. *Journal of the National Comprehensive Cancer Network*. 2014 May 12 (5):621-629. PMID 24812131.
59. Cui Y, Deming-Halverson SL, Shrubsole MJ, Beeghly-Faidel A, Fair AM, Sanderson M, Shu XO, **Kelley MC**, Zheng W. Associations of hormone –related factors with breast cancer risk according to hormone receptor status among white and African American women. *Clinical Breast Cancer*. 2014 December; 14(6):417-25. doi: 10.1016/j.clbc.2014.04.003. PMID 24970715.
60. Li X, Abramson RG, Arlinghaus LA, Kang H, Chakravarthy AB, Abramson VG, Farley J, mayer IA, **Kelley MC**, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Yankeelov TE. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer. *Investigational Radiology*. 2015 April; 50(4):195-204. doi: 10.1097/RLI.000000000000100. PMID: 25360603.
61. Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, Gonzalez-Angulo AM, Mills GB, Red-Brewer M, Meyer IA, Abramson V, Rizzo M, **Kelley MC**, Meszoely IM, Arteaga CL. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor positive breast cancer. *Journal of Clinical Investigation*. 2014 December; 124(12):5490-502. doi: 10.1172/JCI172573. PMID: 25401474.
62. Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Tyrner TC, Essaka DC, Stewart CF, Sosman JA, **Kelley MC**, Ecsedy JA, Johnston JN, Richmond A. MDM2 and aurora kinase inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. *Cancer Research*. 2015 January 1; 75(1):181-93. doi:10.1158/0008-5477.CAN-14-2405. PMID: 25398437.
63. Johnson AS, Crandall H, Dahlman K, **Kelley MC**. Preliminary results from a prospective trial of preoperative combined BRAF and MEK targeted therapy in advanced, BRAF mutation-positive melanoma. *Journal of the American College of Surgeons*. 2015 April 220(4):581-593. PMID 25797743.
64. Hutchinson KE, Johnson DB, Johnson AS, Sanchez V, Kuba MG, Lu P, Chen X, **Kelley MC**, Wang Q, Zhao Z, Kris M, Berger MF, Sosman JA, Pao W. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. *Oncotarget*. 2015 Jun 13, Epub ahead of print, PMID: 26084293.
65. Liu Y, Hawkins OE, Vilgelm AE, Palikowski JS, Ecsedy JA, Sosman JA, **Kelley MC**, Richmond A. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Causes Tumor Regression in Preclinical Mouse Models. *Clinical Cancer Research*. 2015, Dec 1;21(23):5338-48. doi: 10.1158/1078-0432.CCR-15-0293. Epub 2015 Jul 7. PMID: 26152738.
66. Mudigonda TV Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, **Kelley MC**, Hainsworth JD, Sosman JA, Johnson DB. A Phase II Trial of Erlotinib and Bevacizumab for Patients with Metastatic Melanoma. *Pigment Cell and Melanoma Research*. 2015 July 14. Doi: 10.1111/pmcr.12394. Epub ahead

of print. PMID: 26176864.

67. Vilgelm AE, Johnson AC, Prasad N, Yang J, Chen SC, Pawlikowski JA Raman D, Ayers GD, Sosman JA, **Kelley MC**, Ecsedy JA, Shyr Y, Levy SE, Richmond A. Connecting the Dots: Therapy-induced senescence and a tumor suppressive immune microenvironment. *Journal of the National Cancer Institute*, in press, 2015.
68. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, **Kelley MC**, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM, "Melanoma-Specific MHC-II Expression Represents a Tumor-Autonomous Phenotype and Predicts Response to Anti-PD-1/PD-L1 Therapy". *Nature Communications*. 2016 Jan 29 Epub (7):10582.
69. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Baoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, **Kelley MC**, Sosman JA, Johnson BD, Ribas A, Lo RS. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. *Cell* 2016 Mar 24 1(165):35-44.
70. Song C, Lun L, Hugo W, Hong A, Moriceau G, Kong X, Yu CC, Damoiseaux R, **Kelley MC**, Dahlman KB, Sosman JA, Johnson DA, Ribas A, Lo RS. "Residual Melanoma Tumors on MAP Kinase Inhibitor Therapy Undergo Transcriptome-Wide Phenotype Switching". Submitted to *Cancer Cell*, 2015
71. Sai Q, Novitsky S, Hawkins OE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, **Kelley MC**, Sanders M, Moses H, Boothby M, Richmond A. P13K Activity in the Tumor Microenvironment Modulates Mammary Tumor Growth and Metastasis. Submitted *Cancer Discovery*, 2015.
72. Morton DL, Mozillo N, Khashani-Sabet M, Thompson JF, **Kelley MC**, DeConti RD, Lee J, Huth JF, Wagner J, Dalgleish A, Pertschuk D, Nardo C, Elashoff R, Gammon G, Faries M. Long Term Survival after Complete Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. Submitted to *Lancet Oncology*, 2015.
73. Doxie DB, Greenplate AR, Diggins KE, Polikowsky HG, Dahlman KB, Sosman JA, **Kelley MC**, Irish JM. High Content Dissection of Human Melanoma Tumor Heterogeneity During Treatment Using Mass Cytometry. Submitted to *Cancer Cell*, 2015.

BOOK CHAPTERS AND REVIEW ARTICLES

1. Conforti AM, Ollila DW, **Kelley MC**, Morton DL. Update on active specific immunotherapy with melanoma vaccines. *Journal of Surgical Oncology* 66:55-64, 1997.
2. Ollila DW, **Kelley MC**, Gammon G, Morton DL. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. *Seminars in Surgical Oncology* 14:328-336, 1998.
3. **Kelley MC**, Ollila DW, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for melanoma. *Seminars in Surgical Oncology*, 14:283-90, 1998.
4. **Kelley MC**, Giuliano AE. "Lymphatic mapping and sentinel lymphadenectomy for breast cancer" in *The Breast: Comprehensive Management of Benign and Malignant Diseases*. 2nd Ed. KI Bland and EM Copeland III, Eds. W.B. Saunders, pp 1100-1111, 1998.

5. Scoggins CR, **Kelley MC**. Current surgical therapy of rectal cancer. Colorectal Cancer: Index and Reviews 1(4):1-6, 2000.
6. Balch GC, Mithani SK, **Kelley MC**. Intraoperative evaluation of surgical margins in breast-conserving therapy. The Breast: Comprehensive Management of Benign and Malignant Diseases. 3rd Ed., 2003.
7. **Kelley MC**, Hansen N, McMasters K. Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer. The American Journal of Surgery 188(1) 49-61, 2004.
8. Hatmaker AR, Meszoely IM, **Kelley MC**. Surgical management of carcinoma *in situ* and proliferative lesions of the breast. Mastery of Surgery. 5th Ed, JE Fischer and KI Bland, Eds. W.B. Lippincott, Williams and Wilkins, pp 521-530, 2006.
9. **Kelley MC**, Grau AG, Meszoely IM. Surgical management of carcinoma in situ and proliferative lesions of the breast. Mastery of Surgery. 6th Ed, JE Fischer and KI Bland, Eds. W.B. Lippincott, Williams and Wilkins, pp 595-602, 2012.
10. Johnson DB, Puzanov I, **Kelley MC**. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma. Immunotherapy. 2015;7(6):611-9. doi: 10.2217/imt. 15.35. Epub 2015 Jun 22.
11. **Kelley MC**. Immune responses to BRAF targeted therapy in melanoma: Is targeted therapy immunotherapy? *Critical Reviews in Oncogenesis*, in press, 2016.

ABSTRACTS AND POSTER PRESENTATIONS

1. **Kelley MC**, Koppelaar D, Raizada MK, Meyer EM. Pharmacology and Turnover of High Affinity Choline Uptake and Acetylation in Primary Brain Cell Cultures. Presented at the Society of Neuroscience, 1986.
2. **Kelley MC**, Marchand SD, Hocking MP, Sninsky CA. Ketorolac Improves Small Bowel Transit in Rats with Postoperative Ileus. Presented at the 34th Annual University Surgical Resident Conference, Society of University Surgeons, 1992.
3. **Kelley MC**, Langham Jr MR, Hocking MP. Methemoglobinemia is Induced by Endotoxin Through a Nitric Oxide Dependent Pathway. Presented at the American Academy of Pediatrics, Section on Surgery, 1993.
4. Jones RC, **Kelley MC**, Gupta R, Nizze JA, Yee R, Leopoldo Z, Morton DL. Response to Melanoma Cell Vaccine in AJCC Stage III Melanoma: An Immunologic Survival Model. Presented at the Society of Surgical Oncology, 1996.
5. **Kelley MC**, Jones RC, Gupta R, Wanek L, Morton DL. Tumor-Associated Antigen TA-90 Predicts Recurrence, Lymph Node Status and Survival in Stage I and II Melanoma. Presented at the Society of Surgical Oncology, 1996.
6. Jones RC, **Kelley MC**, Gupta R, Morton DL. IgG Subclass Response to Melanoma Cell Vaccine: The Gamma-4 Connection. Proc Am Assoc Cancer Research 37:477, 1996.
7. Gupta R, Nizze JA, Yee R, **Kelley MC**, Leopoldo Z, Stiles A, Dickey A, O'Neill K, Halpin A, Morton DL. Prospective Evaluation of a 90 kD Glycoprotein Tumor-Associated Antigen in Melanoma Patients. Proc Am Soc Clin Oncol 15:93, 1996.

8. Gupta RK, Giuliano AE, **Kelley MC**, Yee R, Leopoldo Z, Morton DL. Clinical Significance of 90 kD Tumor-Associated Antigen-Specific Immune Complexes in Breast Cancer Patients. J Tumor Marker Oncology 11:44, 1996.
9. Essner R, **Kelley MC**, Foshag LJ, Cochran A, Wen D-R, Stern S, Wanek LA, Conforti A, Morton DL. Intraoperative Lymphatic Mapping and Selective Lymphadenectomy in 481 Patients with Early-Stage Melanoma. Presented at the American College of Surgeons, 1996.
10. Essner R, Nguyen TX, **Kelley MC**, Hoon DSB. Human Gastrointestinal Carcinomas Respond to Interleukin-4 Through a Functional IL-2 Receptor Gamma Chain. Presented at the Society of Surgical Oncology, 1997.
11. **Kelley MC**, Nguyen TX, Hoon DSB, Essner R. Regulation of Hepatocyte Growth Factor-Induced Cell Cycle Progression in Pancreatic Carcinoma. Presented at the Society of Surgical Oncology, 1997.
12. Ravindranath MH, Amiri AA, **Kelley MC**, Jones RC, Morton DL. Tumor Progression After Immunotherapy With Melanoma Cell Vaccine is Predicted by the Ratio of IgG to IgM Antibodies to Sialyl-Lewis^x and GM₃ in a Murine Model. Proc Am Assoc Cancer Res. 38:398, 1997.
13. Essner R, Nguyen TX, **Kelley MC**, Hoon DSB. Molecular Role of the Interleukin-2 Receptor Common Gamma Chain Subunit (IL-2R γ c) in Controlling Cell Cycle Progression of Human Non-Small Cell Lung Carcinomas by Interleukin-4. Proc Am Assoc Cancer Res. 38:554, 1997.
14. Essner R, Conforti A, **Kelley MC**, Wanek L, Morton DL. Cost Effective Management of the Inguinal Nodes in Early-Stage Melanoma. Melanoma Res 7(Suppl 1):529, 1997.
15. **Kelley MC**, Bostick P, Bilchik A, Foshag LJ, Essner R, Kuo C, Conrad A, Boasberg PD, Hoon DSB. Molecular Detection of Pancreatic Carcinoma (PC) with a Multiple-Marker RT-PCR Assay. Proc Am Soc Clin Oncol 16:293a, 1997.
16. Bostick P, Sarantou T, Essner R, **Kelley MC**, Glass E, Foshag LJ, Morton DL. Intraoperative Lymphatic Mapping for Early-Stage Melanoma of the Head and Neck. Presented at The Society of Head and Neck Surgeons, 1997.
17. **Kelley MC**, Nguyen TX, Hoon DSB, Essner R. Human Pancreatic Carcinoma Growth and Invasion is Regulated by c-met and Interleukin-4 Receptor Gene Expression. Presented at The Society for Surgery of the Alimentary Tract, 1997.
18. Essner R, Conforti A, **Kelley MC**, Wanek L, Stern S, Morton DL. Efficacy of selective lymphadenectomy as a therapeutic procedure for early-stage melanoma. Presented at The Society of Surgical Oncology, 1998.
19. **Kelley MC**, Leach SD, Simpson JW, Page DL, Beauchamp RD. Routine Review of Histopathology Affects Surgical Management of Melanoma. Presented at the Association for Academic Surgery, 1998.
20. Roberts JR, Leach SD, **Kelley MC**, Tarpley JL, Sharp K, Beauchamp RD. Transthoracic esophagectomy increases life-threatening complications and length of stay compared to transhiatal esophagectomy. Presented at the Society of Thoracic Surgery, 1999.
21. Ollila DW, **Kelley MC**, Hansen N, Giuliano AE. Independent experience of SSO fellowship trained surgical oncologists with lymphatic mapping for breast cancer. Presented at The Society of Surgical Oncology, 1999.

22. Roberts JR, Leach SD, **Kelley MC**, Tarpley JL, Sharp K, Beauchamp RD. Multidisciplinary surgical management and low-dose neoadjuvant radiotherapy decrease operative morbidity and mortality after esophagectomy. Proc Am Soc Clin Oncol 19:290a, 2000.
23. Donovan J, Roberts JR, Beauchamp RD, Berlin J, Chakravarthy A, **Kelley MC**, Pearson AS. Changing patterns of metastasis following complete response to neoadjuvant therapy in patients with adenocarcinoma of the gastroesophageal junction. Presented at the International Gastric Cancer Congress, 2001.
24. Balch GC, Mithani SK, Richards K, Beauchamp RD, **Kelley MC**. Prospective evaluation of the accuracy of lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for locally advanced breast cancer. Society of Surgical Oncology, 2002.
25. **Kelley MC**, Knobel SM, Carbone DP. Dendritic cells loaded with apoptotic melanoma cells slow tumor growth and improve survival in a murine immunotherapy model. Presented at the Society of Surgical Oncology, 2002.
26. Chakravarthy A, **Kelley MC**, Johnson D, Stewart Z, Beauchamp RD, Pearson AS, Merchant NB, Nicholson B, Stein R, Young R, Simpson J, Shyr Y, Pietenpol JA. Neoadjuvant paclitaxel/radiation for stage II/III breast cancer with correlative molecular markers. Proc Am Soc Clin Oncol 21:68a, 2002.
27. McCay J, **Kelley MC**, Schmidt CR, Simpson JF. Desmoplastic melanoma: Rare involvement of sentinel lymph nodes despite deep invasion. Presented at the US and Canadian Academy of Pathology, 2002.
28. Balch GC, Mithani SK, Shyr Y, Pearson AS, **Kelley MC**, Wise P, Chakravarthy A, Berlin J, Beauchamp RD, Merchant NB. Prognostic significance of response to neoadjuvant chemoradiation therapy for rectal cancer. Proc Am Soc Clin Oncol 22:261, 2003.
29. Chakravarthy A, Charaund P, **Kelley MC**, Johnson DH, Stewart Z, Truica C, Beauchamp RD, Pearson AS, Grau A, Simpson J, Shyr Y, Young R, Stein R, Pietenpol JA. Proteomic profiles from serial core biopsies following neoadjuvant paclitaxel/radiation for stage II/III breast cancer. Proc Am Soc Clin Oncol 22:860, 2003.
30. Wyman K, Atkins MB, Hubbard F, McDermott D, **Kelley MC**, Ko Y-J, Viar V, Mier J, Roberts S, Sosman JA. A phase II trial of imatinib mesylate at 800 mg in metastatic melanoma: lack of clinical efficacy with significant toxicity. Proc Am Soc Clin Oncol 22:713, 2003.
31. **Kelley MC**, Knobel SM, Carbone DP. Dendritic cells loaded with apoptotic allogeneic melanoma cells reduce tumor growth and improve survival in a murine immunotherapy model. Presented at the Association for Academic Surgery, 2003.
32. Lawson LL, Sandler M, Martin W, Beauchamp RD, **Kelley MC**. Preoperative lymphoscintigraphy and internal mammary sentinel lymph node biopsy does not enhance the accuracy of lymphatic mapping for breast cancer. Presented at the Southeastern Surgical Congress, 2004.
33. Balch GC, Mithani SK, Simpson J, **Kelley MC**. Accuracy of gross evaluation of surgical margin status in women undergoing partial mastectomy for breast cancer. Presented at the Southeastern Surgical Congress, 2004.
34. Schmidt CR, Yu C, Tarpley JL, Roberts JR, Pearson AS, **Kelley MC**, Ninan M, Berlin J, Chakravarthy A, Smalley WE, Beauchamp RD, Merchant NB. Complete response to neoadjuvant chemoradiation therapy for esophageal cancer does not improve survival. Presented at the Society for Surgical Oncology, 2004.

35. Chakravarthy A, Chaurand P, McLaren B, **Kelley MC**, Truica C, Erskine A, Simpson J, Billheimer D, Caprioli R, Pietenpol JA. Neoadjuvant paclitaxel/radiation for stage II/III breast cancer with correlative molecular markers. Presented at the American Society of Clinical Oncology, 2004.
36. Chakravarthy A, McLaren B, **Kelley MC**, Mayer, I, Brown, C, Johnson KC, Simpson J, Billheimer D, Caprioli R, Pietenpol JA. Developing markers of therapeutic response using serial core biopsies during paclitaxel / radiation therapy in stage II/III breast cancer. Presented at the San Antonio Breast Cancer Symposium, 2004.
37. Forbes RC, Balch GC, **Kelley MC**. Selective Use of Intraoperative Touch Prep Analysis of Sentinel Nodes in Breast Cancer. Presented at the Southeastern Surgical Congress, 2005.
38. **Kelley MC**, Knobel S, Singh S, Sosman J. Cellular responses to PI3K/AKT and MAPK pathway inhibition in melanoma. Presented at the American Association of Cancer Research, 2005.
39. Yankeelov T, Lepage M, Niermann, KJ, Chakravarthy B, Herman CR, McManus K, **Kelley MC**, Meszoely I, Mayer I, Means J, Price RR, Pietenpol J, Gore JC. Quantitative Multi-Parametric MRI Assessment of Breast Cancer Treatment Response. Presented at the 5th Annual SPORE Symposium, 2005.
40. Hatmaker AH, Shipman J, Delbeke D, **Kelley MC**. The impact of FDG-PET staging on the management of patients with melanoma metastatic to the regional lymph nodes. Presented at the Society of Surgical Oncology, 2006.
41. Gray B, Knobel S, Nanney L, **Kelley MC**. Tissue Ischemia Does Not Alter Immunohistochemical Staining of MAPK and PI3K/AKT Pathway Phosphoproteins in a Human Melanoma Xenograft Model. Presented at the Society of Surgical Oncology, 2006.
42. Pitchford CW, **Kelley MC**, Simpson JF. Accuracy of Touch Prep Diagnosis of Breast Cancer Sentinel Lymph Nodes. Presented at the American Association of Pathology Meeting, 2006
43. Yankeelov T, LePage M, Chakravarthy AB, Niermann KJ, Herman CR, McManus K, **Kelley MC**, Mayer IA, Meszoely IM, Gore JC. Fast exchange regime analysis of the response to treatment in human breast cancer. Presented at the International Society for Magnetic Resonance in Medicine Meeting, 2006.
44. Hardesty WM, **Kelley MC**, Caprioli RM. Assessing protein signatures of metastatic melanoma by MALDI-MS. Presented at the American Society of Mass Spectrometry, 2006.
45. Chakravarthy AB, Yankeelov TE, Lepage M, **Kelley MC**, Meszoely IM, Mayer IA, Herman CR, McManus K, Price RR, Gore JC. Monitoring Treatment Response Following Neoadjuvant Chemotherapy Using Dynamic Contrast Enhanced Magnetic Resonance Imaging in Stage II/III Breast Cancer. Presented at the American Society for Therapeutic Radiology and Oncology (ASTRO), 2006
46. Chakravarthy AB., Mayer I.A., Meszoely I., **Kelley M.C.**, Means-Powell J., Johnson D.H., Granja N., Broome E.E., Pietenpol J.A. Phase II study of neoadjuvant dose-dense docetaxel in stage II/III breast cancer. Presented at the San Antonio Breast Cancer Symposium, 2006.
47. Seeley E., Chakravarthy AB., Mi D., De Matos Granja N., Meszoely I., **Kelley M.C.**, Mayer I., Means-Powell J., Johnson K., Caprioli R., and Pietenpol J.A. Histology-directed MALDI-TOF tissue profiling of breast tumors and adjacent stroma: developing markers of therapeutic response. Presented at the 29th Annual San Antonio Breast Cancer Symposium, 2006.

48. American Society of Breast Surgeons Quality and Patient Safety Committee: A Pilot Survey of the Quality of Breast Cancer Care Provided by Surgeons. Presented at the 9th Annual Meeting of The American Society of Breast Surgeons, April 30-May 4, 2008.
49. Chakravarthy AB, Mayer A, Meszoely I, **Kelley MC**, Means-Powell J, Frau AM, Johnson DH, Reddy R, Bauer JA, Pietenpol JA. Phase II study of neoadjuvant dose-dense docetaxel in stage II/III breast cancer. Presented at the American Society of Clinical Oncology, 2008.
50. Mansour AA, Schwartz H, Hatmaker A, Delbeke D, **Kelley MC** Musculoskeletal findings on FDG-PET-CT scans performed for melanoma staging. Presented at the Orthopaedic Research Society, 2008.
51. Hardesty W, **Kelley MC**, Deming M, Low R, Caprioli RM. Protein markers of survival in metastatic melanoma by histology-directed MALDI-MS. Presented at the American Society of Mass Spectrometry, 2008.
52. Keller MD, Majumder SK, **Kelley MC**, Meszoely IM, Boulos FI, Olivares GM, Mahadevan-Jansen A. Autofluorescence and diffuse reflectance spectroscopy and spectral imaging or surgical margin evaluation during breast cancer resection. Presented at the Society of Biomedical Optics, 2008.
53. Yates RB, Viar V, Sosman JA, **Kelley MC**. Parotid sentinel lymph node biopsy: A safe and effective staging procedure for melanoma of the head and neck. Presented at the Society for Melanoma Research, 2010.
54. Yates RB, Viar V, Sosman JA, Stasko T, Shack RB, **Kelley MC**. The Utility of Sentinel Lymph Node Biopsy for Clinical Stage I Merkel Cell Carcinoma. Presented at the Southeastern Surgical Congress, 2011.
55. Li G, Deming-Halverson SL, Cai Q, Fair A, Shrubsole MJ, Shu XO, **Kelley MC**, Zheng, W. Association of UGT2B17 gene copy number variation with breast cancer risk: the Nashville Breast Health Study. Presented at the American Association of Cancer Research, 2012.
56. Xia L, Davis LA, Chakravarthy A, Welch B, Farley J, Mayer IA, Abramson V, Abramson R, **Kelley MC**, Meszoely I, Means J, Grau AM, Bhave SR. Towards Optimization of DCE-MRI Analysis for early prediction of the response of breast cancer patients to neoadjuvant chemotherapy. Presented at the ISMRM Annual Meeting, 2012.
57. Snyder RA, Kauffman R, Puzanov I, Sosman J, **Kelley MC**. Outcome after surgical resection of limited residual or progressive disease in metastatic melanoma patients treated with B-RAF molecular targeted therapy. Presented at the Society of Surgical Oncology, 2012.
58. Isom CA, Yates RB, Viar V, Sosman JA, **Kelley MC**. Long term follow-up confirms the safety and efficacy of parotid sentinel node biopsy as a staging procedure for head and neck melanoma. Accepted for Presentation at the Society of Surgical Oncology, 2014.
59. Irish JA, Doxie D, Greemplate A, Diggins K, Polikowsky H, Dahlan K, **Kelley MC**. High content dissection of human melanoma tumor heterogeneity during treatment using mass cytometry. Presented at the CYTO cytometry meeting, 2015.
60. Lavender N, Yang J, Sai J, Novitsky S, Horton L, Johnson A, Abramson V, Mayer I, Meszoely IM, **Kelley MC**, Richmond A. P13K inhibitors reduce breast cancer tumor growth and enhance anti-tumor leukocyte activity. Submitted to the American Association of Cancer Research, 2016.

INVITED LECTURES

1. University of Florida, Gainesville, FL. Surgery Grand Rounds. "Recent Advances in the Management of Melanoma". March 1996.
2. Arkansas Cancer Research Center, Little Rock, AK. Surgery Grand Rounds. "Recent Advances in the Management of Melanoma". February 1997.
3. Vanderbilt University Medical Center, Nashville, TN. Obstetrics and Gynecology Grand Rounds. "Evaluation and Management of Benign Breast Disease". October 1, 1997.
4. American Cancer Society Breast Cancer Forum, Nashville, TN. "Patient Choices: Surgical Treatment Options for Breast Cancer". October 18, 1997.
5. Vanderbilt University Medical Center, Nashville, TN. Surgery Grand Rounds. "Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer". November 1, 1997.
6. Bedford County Medical Center, Shelbyville, TN. "Recent Advances in the Management of Breast Cancer". November 6, 1997.
7. Vanderbilt University Medical Center, Nashville, TN. Medical Oncology Grand Rounds. "Surgical Management of Primary Breast Cancer" February 3, 1998.
8. Vanderbilt University Medical Center, Nashville, TN. Dermatology Grand Rounds. "Immunotherapy for Melanoma". February 12, 1998.
9. East Tennessee State University, Johnson City, TN. Surgery Grand Rounds. "Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer". March 14, 1998.
10. Tumor Registrar's Association of Tennessee Annual Meeting. Nashville, TN. "Current Management of Breast Cancer". March 20, 1998.
11. Clarksville Memorial Hospital, Clarksville, TN. "Recent Advances in the Surgical Management of Breast Cancer". July 17, 1998.
12. Maury Regional Hospital, Columbia, TN. "Recent Advances in the Management of Breast Cancer". October 15, 1998.
13. Vanderbilt University Medical Center, Nashville, TN. Department of Obstetrics and Gynecology Grand Rounds. "Recent Advances in the Management of Breast Cancer". February 17, 1999.
14. Vanderbilt University Medical Center, Nashville, TN. 1999 Lonnie S. Burnett Vanderbilt OB-GYN Society Meeting. "Tamoxifen and other SERMs for the Prevention of Breast Cancer". June 4, 1999.
15. The Genesys Hurley Cancer Institute, Hurley Medical Center, Flint, MI. Controversies in the Multi-Modality Treatment of Breast Cancer. "Current Trends in the Surgical Management of Breast Cancer". October 13, 1999.
16. Cookeville Regional Cancer Center, Cookeville, TN. "Recent Advances in the Surgical Management of Breast Cancer". October 14, 1999.

17. Vanderbilt Department of Radiology, Nashville, TN. "Recent Advances in the Surgical Management of Breast Cancer". October 23, 1999.
18. Vanderbilt University School of Medicine, Nashville, TN. Women's Health Conference. Sponsored by Wyeth-Ayerst Labs, AstraZeneca Pharmaceuticals and UnitedHealthcare. "Recent Advances in the Detection, Treatment, and Prevention of Breast Cancer. November 20, 1999.
19. Vanderbilt University School of Medicine, Nashville, TN. High-Risk Obstetrics Seminar. Specialty Workshop: "Breast Cancer". December 3, 1999.
20. Bedford County Medical Center, Shelbyville, TN. "Breast Cancer Risk Evaluation and Management". January 6, 2000.
21. Vanderbilt-Ingram Cancer Center Affiliate Network, Nashville TN. "Clinical Trials for Women at High Risk of Developing Breast Cancer". March 4, 2000.
22. Cumberland Regional Medical Center, Crossville, TN. "Recent Advances in the Management of Breast Cancer". May 2, 2000.
23. Bedford County Medical Center, Shelbyville, TN. "Recent Advances in the Management of Melanoma". June 22, 2000.
24. Heartland Medical Center, Elizabethtown KY. "Recent Advances in the Management of Melanoma". August 19, 2000.
25. Harton Regional Medical Center, Tullahoma, TN. "Breast Cancer Risk Evaluation and Management". September 14, 2000.
26. Maury Regional Hospital, Columbia, TN. "Breast Cancer Risk Evaluation and Management". October 12, 2000.
27. Susan B. Komen Foundation Breast Cancer Symposium, Nashville, TN. "Breast Cancer Diagnosis and Surgical Treatment". March 31, 2001.
28. Vanderbilt University Medical Center Division of Ambulatory Medicine, Nashville, TN. "Evaluation of Common Breast Complaints". October 5, 2001.
29. Vanderbilt University Medical Center, Nashville, TN. Department of Obstetrics and Gynecology Grand Rounds. "Update on the Management of Melanoma". December 5, 2001.
30. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Prophylactic Mastectomy: Indications, Risks, Benefits" January 18th, 2002.
31. Vanderbilt University Medical Center, Nashville TN. Cancer Genetics Symposium "Breast Cancer Risk Reduction Strategies" January 19th, 2002.
32. The University of Florida, Gainesville FL. Edward M. Copeland III Scientific Symposium. "New Approaches to Immunotherapy of Melanoma" March 1st, 2002.
33. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Immunotherapy of melanoma: From Bench to Bedside and Back Again" September 13th, 2002.

34. Vanderbilt University Medical Center, Nashville, TN. Department of Cancer Biology. "Tumor Immunology and Immunotherapy" November 11th, 2002.
35. Society of Surgical Oncology, Los Angeles CA. Moderator, Breast Cancer Parallel Session, March 7th, 2003.
36. Vanderbilt University Medical Center, Nashville, TN. Melanoma Research Conference. "Preclinical Studies of Molecular Targeted Therapy of Melanoma: A Work in Progress" March 19th, 2003.
37. Cumberland Regional Medical Center, Crossville, TN. "Controversies in the Treatment of Melanoma". June 3, 2003.
38. Maury Regional Hospital, Columbia, TN. "Current Management of Melanoma". September 10, 2003.
39. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Evaluation and Management of Common Breast Conditions" October 3, 2003.
40. Bellevue Mall, Nashville, TN. "Cancer Answer Evening: Breast Cancer – Ask the Expert" October 7, 2003.
41. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Breast Cancer Treatment" October 10, 2003.
42. Vanderbilt University Medical Center, Nashville, TN. "Cancer Answer Evening: Breast Cancer – The Crusade Marches On" October 7, 2003.
43. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Melanoma Management" October 24, 2003.
44. Vanderbilt University Medical Center, Nashville, TN. Department of Cancer Biology. "Tumor Immunology and Immunotherapy" November 3, 2003.
45. Erlanger Medical Center, Chattanooga TN. Department of Surgery Grand Rounds. "Melanoma Management" November 5, 2003.
46. Williamson County Medical Center, Franklin TN. "Recent Advances in the Surgical Treatment of Breast Cancer" November 6, 2003.
47. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Resident Teaching Conference. "Tumor Immunology and Immunotherapy" December 12, 2003.
48. Vanderbilt University Medical Center, Nashville, TN. Oncology Conference. "Breast Cancer Risk Evaluation and Management". January 23, 2004.
49. Vanderbilt University Medical Center, Nashville, TN. School of Nursing Grand Rounds. "Management of Common Breast Conditions" April, 2004.
50. Vanderbilt University Medical Center, Nashville, TN. Oncology Conference. "Surgical treatment of melanoma". April 26, 2005.

51. Vanderbilt University Medical Center, Nashville, TN. Multidisciplinary Melanoma Symposium. "Sentinel lymph node biopsy for melanoma". September 16, 2005.
52. Vanderbilt University Medical Center, Nashville, TN. Cancer Biology Research Seminar. "Cellular responses to MAP kinase and PI-3 kinase / AKT pathway inhibition in melanoma. February 13, 2006.
53. Vanderbilt University Medical Center, Nashville, TN. Surgical Oncology Research Seminar. "Pre-clinical models of molecular therapy targeting the MAP kinase and PI-3 kinase / AKT pathways in melanoma". February 20, 2006.
54. Vanderbilt University Medical School, Nashville, TN. Introduction to Clinical Medicine Lecture. "Clinical evaluation of breast diseases". April 18, 2006.
55. Vanderbilt University Medical School, Nashville, TN. Primary Care Update. "Evaluation of palpable abnormalities of the breast". May 18, 2006.
56. Vanderbilt University Medical Center, Nashville, TN. Plastic Surgery Teaching Conference. "Melanoma Update: 2006". June 22, 2006.
57. University of Tennessee, Knoxville TN. Department of Surgery Grand Rounds. "Treatment of High-Risk Melanoma: Progress or Futility?" March 29, 2007.
58. Community Methodist Hospital, Hendersonville, KY. Oncology Conference. "Breast cancer risk evaluation and management" August 29, 2007.
59. Vanderbilt University Medical Center, Nashville, TN. Department of Surgery Grand Rounds. "Melanoma 2007: Have we made any progress?" September 7th, 2007.
60. Tennessee Academy of Physician's Assistants Annual Meeting, Gatlinburg, TN. "Breast cancer screening and treatment, 2007" October 9, 2007.
61. Vanderbilt University Medical Center MCE Grand Rounds. "Surgical treatment of breast cancer: Practical information for OR staff and anesthesia providers" January 9, 2008
62. University Medical Center, Lebanon, TN. "Breast cancer risk evaluation and management" February 12th, 2008.
63. Vanderbilt University Medical Center, Nashville, TN. Department of Dermatology Grand Rounds. "Surgical treatment of high-risk melanoma" April 9th, 2009.
64. Northcrest Medical Center, Springfield TN. "Surgical treatment of high-risk melanoma" June 18th, 2009.
65. Heritage Medical Group, Nashville TN. "Breast cancer risk evaluation and management" September 18th, 2009.
66. Community Methodist Hospital, Henderson, KY. "Current Management of Breast Cancer." October 2010
67. Cancer Centers of Florida, Orlando, FL. "Updates in Community Oncology 2011: Current and Future Directions in the Treatment of Malignant Melanoma." November 15, 2011.

68. Memphis Oncology Journal Club, Memphis, TN. "Multidisciplinary Management of Advanced Melanoma: The evolving role of the surgeon in personalized cancer care." February 28, 2013.
69. Baptist Health System Symposium, Louisville, KY. "Surgical Treatment of Breast Cancer: Where are we now and where are we going?" November 16, 2013.
70. National Comprehensive Cancer Network, NCCN / GSK Investigator's Meeting, Hollywood FL. "Biomarkers of response and resistance to BRAF targeted therapy in a pre-surgical model of advanced, operable melanoma – A progress report". March 13, 2014.
71. CHI – Memorial Hospital, Chattanooga, TN. "Cancer Care Today – Melanoma" February 28, 2015.
72. WGOW 102.3 FM, Chattanooga, TN. "Chewin' the Chatt", Host – Jed Mescon, "Melanoma and Skin Cancer" June 24th, 2015.
73. WRCB Channel 3, Chattanooga, TN. "3 Plus You", Host – Jed Mescon, "Melanoma and Skin Cancer" September, 2015.
74. American College of Surgeons, Chicago, IL. Melanoma, 2015: Integrating New Knowledge into Your Clinical Practice. Presenter and Moderator. October 7, 2015
75. Society of Surgical Oncology, Boston MA: Melanoma Parallel Session, Moderator. March 4, 2016